Aggravation of A lzheimer's disease due to the COX ‐2‐mediated reciprocal regulation of IL ‐1β and A β between glial and neuron cells

Summary A lzheimer's disease ( AD ) is the most common form of dementia and displays the characteristics of chronic neurodegenerative disorders; amyloid plaques ( AP ) that contain amyloid β‐protein (Aβ) accumulate in AD , which is also characterized by tau phosphorylation. Epidemiological evidence has demonstrated that long‐term treatment with nonsteroidal anti‐inflammatory drugs ( NSAID s) markedly reduces the risk of AD by inhibiting the expression of cyclooxygenase 2 ( COX ‐2). Although the levels of COX ‐2 and its metabolic product prostaglandin ( PG ) E 2 are elevated in the brain of AD patients, the mechanisms for the development of AD remain unknown. Using human‐ or mouse‐derived glioblastoma and neuroblastoma cell lines as model systems, we delineated the signaling pathways by which COX ‐2 mediates the reciprocal regulation of interleukin‐1β ( IL ‐1β) and Aβ between glial and neuron cells. In glioblastoma cells, COX ‐2 regulates the synthesis of IL ‐1β in a PGE 2 ‐dependent manner. Moreover, COX ‐2‐derived PGE 2 signals the activation of the PI 3‐ K / AKT and PKA / CREB pathways via cyclic AMP ; these pathways transactivate the NF ‐κB p65 subunit via phosphorylation at S er 536 and S er 276, leading to IL ‐1β synthesis. The secretion of IL ‐1β from glioblastoma cells in turn stimulates the expression of COX ‐2 in human or mouse neuroblastoma cells. Similar regulatory mechanisms were found for the COX ‐2 regulation of BACE ‐1 expression in neuroblastoma cells. More importantly, Aβ deposition mediated the inflammatory response of glial cells via inducing the expression of COX ‐2 in glioblastoma cells. These findings not only provide new insights into the mechanisms of COX ‐2‐induced AD but also initially define the therapeutic targets of AD .